A Study of Japanese Rheumatoid Arthritis Participants

Summary

The objective of this study is to evaluate the safety and tolerability of 48 weeks subcutaneous (SC) dosing with LY2127399 for participants who have participated in a prior LY2127399 clinical study. At the end of the 48-week treatment period, participants will participate in a 24-week follow-up period. Additional follow up after Week 72 may continue to assess B-cell recovery.

Timeline

Start

2010-05

Primary completion

2013-09

Completion

2014-03

Drugs

Indications